Skip to main content
Clinical Trials/NCT03485924
NCT03485924
Terminated
Not Applicable

Endoscopic Ultrasound With Fine Needle Biopsy Versus Fine Needle Aspiration With On-Site Cytopathology in the Evaluation of Solid Pancreatic Masses: Randomized Single Blinded Clinical Trial

Johns Hopkins University1 site in 1 country35 target enrollmentApril 12, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Fine Needle Aspiration
Sponsor
Johns Hopkins University
Enrollment
35
Locations
1
Primary Endpoint
The Diagnostic Accuracy of Fine-needle Biopsy (FNB) Sampling Without Rapid Onsite Evaluation (ROSE) and the Fine Needle Aspiration (FNA) With ROSE in Pancreatic Mass Lesions
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

The objective of this paired cohort study is to evaluate the diagnostic accuracy of Endoscopic Ultrasound-fine needle aspiration (EUS-FNA) with rapid onsite evaluation (ROSE) compared to EUS-fine needle biopsy (EUS-FNB) without ROSE. If EUS-FNB without ROSE is shown to be non-inferior to the current standard of care of EUS-FNA with ROSE in pancreatic lesions, this study has the potential to make EUS-guided tissue acquisition more economical (with elimination for the need for cytopathology staff onsite) as well as provide core histological specimen without sacrificing the overall diagnostic yield.

Detailed Description

Endoscopic ultrasound (EUS) guided fine needle aspiration (EUS-FNA) is the primary technique for tissue acquisition for pancreatic lesions. Despite widespread adoption of the techniques, the diagnostic yield of EUS-FNA for pancreatic lesion is highly variable, with sensitivities ranging from 64-95%, specificities ranging from 75-100% and overall diagnostic accuracy ranging from 78-95%. Despite its mainstay as the primary technique for tissue acquisition, EUS-FNA has several limitations. The standard EUS-FNA does not routinely provide core biopsy specimen with preserved tissue architecture, which is required for immunohistochemical staining and for definitive diagnosis of conditions, such as lymphoma, gastrointestinal stromal tumors, Immunoglobulin G (IgG)-4-associated lymphoplasmacytic sclerosing pancreatitis. Furthermore, the diagnostic yield of EUS-FNA is highly dependent on the availability of bedside cytotechnologist or cytopathologist for rapid onsite evaluation (ROSE), which increases the overall cost required to perform EUS-FNA. Recently, multiple dedicated EUS fine needle biopsy (FNB) needles have been developed to obtain core specimens. Early small studies have shown promising results with these EUS-FNB needles. The objective of this paired cohort study is to evaluate the diagnostic accuracy of EUS-FNA with ROSE compared to EUS-FNA with ROSE. If EUS-FNB without ROSE is shown to be non-inferior to the current standard of care of EUS-FNA with ROSE in pancreatic lesions, this study has the potential to make EUS-guided tissue acquisition more economical (with elimination for the need for cytopathology staff onsite) as well as provide core histological specimen without sacrificing the overall diagnostic yield.

Registry
clinicaltrials.gov
Start Date
April 12, 2018
End Date
July 26, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient ≥ 18 years of age referred for EUS-guided biopsy for pancreatic mass lesions

Exclusion Criteria

  • Refusal to consent form
  • Uncorrectable coagulopathy (INR \> 1.5)
  • Uncorrectable thrombocytopenia (platelet \< 50,000)
  • Uncooperative patients
  • Pregnant women (women of childbearing age will undergo urine pregnancy testing, which is routine for all endoscopic procedures)
  • Medically unstable for sedation
  • Entirely cystic lesions
  • Lesions inaccessible to EUS

Outcomes

Primary Outcomes

The Diagnostic Accuracy of Fine-needle Biopsy (FNB) Sampling Without Rapid Onsite Evaluation (ROSE) and the Fine Needle Aspiration (FNA) With ROSE in Pancreatic Mass Lesions

Time Frame: 6 months from the initial biopsy

Diagnostic accuracy will be defined as (true positive + true negative)/all participants in the arm.

Secondary Outcomes

  • Specimen Adequacy(Post-procedure one week)
  • Number of Histology Cores Obtained(Post-procedure one week)
  • Median Number of Passes(6 months from the initial biopsy)
  • Number of Technical Failures(After the procedure, an average of 1 hour)

Study Sites (1)

Loading locations...

Similar Trials